Find Drugs for Cardiology/Vascular Diseases in Phase II/ Phase III Clinical Development in JAPAN

Lead Product(s): HLCM051

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

The SSC candidate of Healios (HLCM051) is in an ischemic stroke pivotal phase 2/3 trial in Japan in which it offers the potential to provide effective treatment over a much longer treatment window.